Oncology & Cancer

Bevacizumab active in HIV-linked Kaposi's sarcoma

(HealthDay) -- For patients with HIV-associated Kaposi's sarcoma (HIV-KS), bevacizumab is tolerated and induces a response in some patients, according to a study published online March 19 in the Journal of Clinical Oncology.

Oncology & Cancer

Bevacizumab doesn't prolong survival in stage II-III colon CA

(HealthDay)—For patients with stage 2 to 3 colon cancer, the addition of bevacizumab to modified fluorouracil, leucovorin, and oxaliplatin (FOLFOX6) does not prolong disease-free or overall survival, according to a study ...

Medications

Addition of maintenance olaparib slows advanced ovarian cancer

(HealthDay)—Compared with placebo, the addition of olaparib to maintenance therapy with bevacizumab is associated with a significant progression-free survival benefit for patients with advanced ovarian cancer, according ...

Oncology & Cancer

Promising cervical cancer study

Research on cervical cancer performed by a physician at the University of Arizona Cancer Center at St. Joseph's Hospital and Medical Center has been published in the New England Journal of Medicine. The multi-site research ...

Oncology & Cancer

Phase III data in treatment of renal cell carcinoma reported

New results from phase III trials exploring treatment options for patients with advanced renal cell carcinoma were released at the ESMO 2012 Congress of the European Society for Medical Oncology in Vienna.

page 6 from 12